Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization
Preprint
Abstract
Background There is an urgent need for treatments to prevent the progression to severe COVID-19 and hospitalization. Methods This is a double-blind randomized multicenter study in 36 centers in the U.S. and Puerto Rico investigating the potential of a five-day treatment with nitazoxanide 300 mg extended release tablets in 379 outpatients with mild or moderate laboratory-confirmed COVID-19 with an onset of symptoms no more than 72 hours before inclusion. Key objectives were reduction of duration of symptoms (primary), progression to severe illness (key secondary), hospitalization and viral load. Results Time to sustained response was not reduced by nitazoxanide (median: 13.28 and 12.35 days for nitazoxanide and placebo). Nitazoxanide treatment provided an 85% reduction in the progression to severe COVID-19 (1/184, [0.5%] nitazoxanide vs. 7/195, [3.6%] placebo). In subjects at high-risk according to CDC criteria, 1/112 (0.9%) of nitazoxanide-treated subjects and 7/126 (5.6%) of placebo-treated subjects experienced progression to severe COVID-19. Treatment led to a 79% reduction in the rate of hospitalization (1/184 [0.5%] nitazoxanide vs. 5/195 [2.6%] placebo). The proportions positive for SARS-CoV-2 RNA and viral load at days 4 and 10 were not reduced. Nitazoxanide was safe and well tolerated. Conclusions Treatment of mild or moderate COVID-19 with a five-day course of oral nitazoxanide was safe and well tolerated and was associated with an 85% reduction in the progression to severe illness.Keywords
All Related Versions
- Published version: eClinicalMedicine, 45, 101310.
This publication has 21 references indexed in Scilit:
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitroCell Research, 2020
- Nitazoxanide inhibits paramyxovirus replication by targeting the Fusion protein folding: role of glycoprotein-specific thiol oxidoreductase ERp57Scientific Reports, 2018
- Performance of the inFLUenza Patient-Reported Outcome (FLU-PRO) diary in patients with influenza-like illness (ILI)PLOS ONE, 2018
- Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirusJournal of Infection and Public Health, 2016
- A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugsAntiviral Research, 2015
- Nitazoxanide: A first-in-class broad-spectrum antiviral agentAntiviral Research, 2014
- Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trialThe Lancet Infectious Diseases, 2014
- Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected miceInternational Immunopharmacology, 2012
- Thiazolides, a New Class of Anti-influenza Molecules Targeting Viral Hemagglutinin at the Post-translational LevelJournal of Biological Chemistry, 2009
- Potential for Hepatitis C Virus Resistance to Nitazoxanide or TizoxanideAntimicrobial Agents and Chemotherapy, 2008